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Abstract 
Silver enhanced in situ hybridization (SISH) is an emerging tool for the 
determination of the Her-2/neu amplification status in breast cancer. SISH is 
technically comparable to fluorescence in situ hybridization (FISH) but does 
not require a fluorescence microscope for its interpretation. While recent 
studies on histological evaluations of SISH are promising, we aimed to 
evaluate its performance on 71 cytologic breast cancer specimens with the 
new combined Her-2/Chr.17 probe. Her-2/neu status as routinely determined 
by FISH was available for all patients. We found SISH signals in cytologic cell 
blocks and smear specimen easy to evaluate in most cases. Small numbers 
of tumor cells and difficulties in identifying tumor cells in lymphocyte-rich 
backgrounds were limiting factors. Her-2/neu status, as determined by Her-
2/Chr17 SISH, was basically identical to the results of the corresponding 
FISH. The discrepancies were mainly due to the heterogeneity of Her-2/neu 
amplification in the tumor tissue. Inter-observer agreement for the SISH 
evaluation was high (kappa value: 0.972). 
We conclude that Her-2/Chr17 SISH is a useful and accurate method for the 
evaluation of the Her-2/neu gene amplification status in cytologic breast 
cancer specimens, particularly in metastatic breast cancer lesions. The 
advantages of signal permanency and bright field microscopic result 
interpretation make this technique an attractive alternative to the current 
FISH-based gold standard. 
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Introduction 
Silver enhanced in situ hybridization (SISH) is a recently introduced new 
bright-field in situ-hybridization technique for the detection of DNA-signals, 
mainly used for cancer genotyping. The technique is based on enzymatic 
metallography and metallic silver deposition (7). Resulting silver complex 
deposits are stable over time and furthermore allow surgical pathologist to 
assess the signal with conventional bright-field microscopes instead of 
fluorescence microscopes necessary for fluorescence in situ hybridization 
(FISH). Until now, the SISH technique has mainly been promoted for the 
assessment of the Her-2/neu amplification status in breast cancer patients. 
The most recent SISH version allows for a combined detection of Her-2/neu 
and chromosome 17 including a chromogenic detection for the latter one.  
The identification of invasive breast carcinomas with amplification of the 
human epidermal growth receptor 2 gene (ERBB2 or Her-2/neu) has, like the 
assessment of the hormone receptor status, become an essential standard 
procedure for the assessment of newly diagnosed breast cancers (6, 8). This 
is mainly due to the availability of effective treatment of tumors with over-
expression of Her-2 with humanized anti-Her-2 antibodies. Over-expression of 
Her-2/neu is found in approximately 15% of breast cancers and it is only in 
these patients that the above mentioned therapy is beneficial and cost-
effective (1, 5, 11, 15). The additional costs for an anti-Her-2 antibody therapy 
have been estimated between 40.000 and 50.000 US$ (equaling 25.000-
35.000 €) (10). Therefore a high reliability and robustness in the assessment 
of the Her-2/neu amplification status is mandatory.  
Fine needle aspirations (FNA) or body cavity fluids containing breast cancer 
cells are common in cytological routine work. The role of FNA in the diagnosis 
of metastatic or disseminated disease is undisputed, while the diagnosis of 
the primary tumor is more controversial, being well established only in few 
specialized centers (12, 16). Requests for testing of Her-2/neu amplification 
status on cytological specimens, mainly in the setting of a metastatic disease, 
have been increasing constantly over the last few years.  
 
According to the last ASCO Guidelines, two different ways of testing are 
commonly used to determine the Her-2 status in surgical pathology 
specimens (19). They comprise the detection of the Her-2 protein and/or of 
the Her-2/neu gene amplification status by immunohistochemistry or by 
fluorescence, chromogenic or silver labeled in situ hybridization methods 
(FISH, CISH, SISH). Due to insufficiencies of the immunohistochemistry in 
terms of inter-observer and inter-laboratory variability, the in situ hybridization 
method, particularly the FISH analysis is currently regarded as the gold 
standard (17). However, the need for special microscopic equipment and the 
rather quick fading of fluorochromes over time are relevant disadvantages of 
the FISH technique.  
In this study, we analyzed the usability and reliability of the SISH technique for 
the determination of the Her-2/neu amplification status in different cytologic 
breast cancer specimens in comparison to corresponding FISH results.  
 
Material and Methods 
Patients and samples 
Seventy-one patients diagnosed with breast cancer at the Division of Cytology 
of the Institute of Surgical Pathology of the University Hospital Zurich, with 
known Her-2 FISH status, were included in this study. Twentythree of the 
specimens originated from 2006 to 2008 and were selected due to their 
amplified Her-2/neu status in FISH. The remaining 48 specimens were from 
consecutive patients in 2009. The study was approved by the project review 
board at our institution and no further ethical approvals were necessary. The 
median patient age was 62 years (range 29 to 86 years). The cytological 
samples consisted of 34 (47.9%) FNAs of primary breast tumors, 25 (35.2%) 
FNAs of metastases (22 lymph nodes and 3 soft tissue masses) and 11 
(15.5%) body cavity fluids (9 pleural effusions and 2 abdominal effusions) as 
well as 1 mammary secretion. For 64 patients histological data on the primary 
tumor were available: Fifty-eight (90.6%) had invasive ductal carcinomas, four 
(6.3%) invasive lobular carcinomas and two (3.1%) carcinomas of other 
histological types. The pT tumor status was pT1: 22 cases (34.4%), pT2: 30 
(46.9%), pT3: 8 (12.5%) and pT4: 4 (6.3%) respectively. The histological 
tumor grade was G1: 2 (3.1%), G2: 18 (28.1%) and G3: 42 (65.6%). For two 
cases no grading was given due to too small amounts of tumor in the core 
biopsy specimens. Results of the Her-2/neu FISH analysis were available for 
all patients. In 47 (66.2%) cases FISH and SISH analyses were performed on 
biopsies and/or FNAs of exactly the same primary (36 out of 47 cases) or 
metastatic (6 out of 47 cases) tumor nodules or fluid specimen (5 out of 47 
cases). The combinations of specimen preparations for these 47 cases were 
as follows: 19 (40.4%) cases: SISH on cell block and FISH on histologic 
specimen; 11 (23.4%) cases: SISH on smear and FISH on histologic 
specimen; 16 (34.0%) cases: SISH and FISH on cell block; 1 (2.1%) case: 
SISH on smear and FISH on cell block.  
In the remaining 24 cases the SISH was mostly (79.2%) performed on 
metastatic deposits while the FISH was done on the primary tumor. In four 
cases SISH and FISH were performed on different metastatic deposits and in 
one case the SISH was done on the primary tumor and the FISH on the 
metastasis. The combinations of specimen preparations for these 24 cases 
were as follows: 12 (50.0%) cases: SISH on cell block and FISH on histologic 
specimen; 11 (45.8%) cases: SISH on smear and FISH on histologic 
specimen; 1 (4.2%) case: SISH and FISH on cell block.  
The median time lag between the specimen taken for the FISH and the one 
taken for SISH analysis was one week. Only in four cases was this time lag 
more than 8 weeks.  
 
Silver enhanced in situ hybridization (SISH) 
SISH was performed according to the manufacturers’ protocol either on 
paraffin slides from the cytology cell blocks or on Papanicolau stained direct 
smears. Cytologic cell blocks were prepared by coagulating the FNA/fluid cell 
pellets with a mixture of plasma and thrombin and further standard processing 
of the clot to paraffin blocks. INFORM HER-2 DNA probe was detected with 
ultraView SISH Detection Kit and INFORM Chromosome 17 probe with the 
ultraView AP red SISH Detection Kit (780-4332 &780-4331, Ventana Medical 
Systems, Tucson, AZ, USA).The whole process was completely automated 
using Ventana’s Benchmark autostainers. The protocol of the SISH staining 
has been described before (7). The specimens were briefly counterstained 
with Ventana Hematoxilin II. 
 
Fluorescence in situ hybridization (FISH) 
Deparaffinizing, pre-treatment and protease digestion procedures followed the 
ABBOTT/Vysis PathVysion Her-2 DNA Probe Kit protocol (VP-200 program). 
Probe mixes were hybridized at 37°C between 14 and 20h, washed in Rapid-
Wash-Solution I at 73°C for 5min, Rapid-Wash-Solution II and H2O for 7min, 
air dried and counterstained with DAPI. A minimum of 20 nuclei of invasive 
tumor cells were scored using a Olympus BX61 microscope with fluorescence 
equipment (Olympus Cooperation, Tokyo, Japan). 
 
SISH scoring 
The SISH signals were scored by counting the signals for Her-2 (black) and 
chromosome 17 (red) according to the manufacturers recommendation in 20 
cancer cell nuclei. The Her-2 signals were divided by the chromosome 17 
signals. According to the manufacturers manual the threshold for amplification 
was a value larger than 2.2. Results below 1.8 were considered non-amplified 
and those between both values equivocal. The evaluations were done 
independently by two pathologists (FRF and PKB) on conventional Zeiss 
Axioscope 40 Microscopes with 400x magnification. (Carl Zeiss MicroImaging, 
Jena, Germany). Both pathologists were blinded to clinicopathologic 
parameters, previous FISH results and the SISH results of each other.  
  
Statistical analysis 
Statistical analysis was performed using SPSS, version 18.0. P values < 0.05 
were considered significant. 
 
Results 
SISH results 
Altogether, 50 Her-2 SISH results were obtained from cytologic cell blocks 
and 23 from direct smears. For two patients the analysis was done on the cell 
block as well as on the cytologic smear. In these two patients the SISH results 
were identical on both media for both evaluating pathologists and also 
consistent with the FISH results.  
The SISH signals were easily detectable in almost all cases (Figure 1) and 
both red and black signals were unchanged in the intensity after 7 months. In 
comparison to the black Her-2 signals the red chromosome 17 signals 
appeared generally stronger and bigger. In terms of Her-2/neu amplification 
status in the SISH analyses, 39 (54.9%) cases were considered non-
amplified, 31 (43.7%) were amplified and one (1.4%) was considered 
equivocal.  
 
Comparison of Her-2 SISH and FISH results (Table 1) 
From the 39 cases that were considered non-amplified in the SISH analysis 
36 (92.3%) were also non-amplified in the FISH analysis.  
Three cases (7.7%) were considered amplified in the FISH analysis. One of 
the discrepant SISH analyses was applied on a cell block, the other two on 
cytologic smears. All three samples corresponded to fine needle aspirations of 
the breast and corresponding FISH was performed on the histologic sample of 
the same tumor nodule. On review of these cases, in two cases the FISH 
analysis showed only heterogeneous Her-2/neu amplification with several 
clearly non-amplified tumor cells. On review of the corresponding SISH 
analyses in one of the cases very few definitely amplified cells could be 
detected. The third case was unequivocally amplified in the histological FISH 
analysis. However, the smear showed prominent air drying artifacts which 
were already noted during evaluation and it additionally included cells with 
polysomy. Nevertheless, also in the informed review no amplified cells could 
be detected in the SISH in this case. 
From the 31 cases that were amplified in the SISH, 30 (96.8%) were also 
considered amplified in the FISH with one being considered equivocal. The 
equivocal FISH (histologic sample of the same tumor nodule) was commented 
to be considered amplified in the report due to heterogeneity.  
One case was considered equivocal in the SISH while it was considered 
amplified in the FISH analysis (both on cell blocks of the same tumor nodule). 
The repeat of the FISH result showed definitely amplified cells but was also 
rather heterogeneous.  
The inter-observer consistency between the two pathologists independently 
evaluating the Her-2 SISH was excellent with a kappa value of 0.972. The 
only discrepant case was considered amplified by one and non-amplified by 
the other pathologist. The FISH analysis in this case was considered 
amplified. In the revision of the case on a multiheaded microscope consensus 
in terms of amplification was reached. However, both SISH and FISH were 
only just above the positivity limit for this case. 
Discussion 
In the present study, the Her-2/neu amplification status of a series of breast 
cancer cases was examined in cytology specimens by the recently introduced 
SISH technique. Results of our study showed high interobserver 
reproducibility in SISH signal interpretation between two cytologists and a 
high concordance with FISH results. 
Despite being more expensive, the in situ hybridization techniques are 
considered to be advantageous in terms of reliability for the determination of 
the predictively important Her-2 status in breast cancer patients in comparison 
to immunohistochemistry (17).  
The costs of SISH are comparable to that of FISH. On the Ventana platform, 
the SISH is completely automated, which ensures consistency and 
reproducibility of methodology and results. SISH results were available in up 
to six hours. The major advantage of Her-2 SISH over the current standard 
FISH is the stability of the signal over time. Furthermore, unlike with FISH, 
conventional bright-field microscopes are sufficient for evaluation, which is 
clearly an advantage over time-consuming FISH evaluation sessions. 
The first evaluation of Her-2 SISH was performed by Dietel et al. on breast 
cancer tissue samples (7). In the meantime several other groups were able to 
validate these results on breast cancer tissue (2-4, 9, 18). Like Dietel and 
colleagues, they found a good reproducibility of the results and high 
concordance with immunohistochemistry, polymerase chain reaction and with 
other in situ techniques (including FISH). Our results are strongly consistent 
with those of the research groups mentioned in terms of reliability and inter-
observer consistency. In line with these studies we experienced only a few 
equivocal cases. This may be due to the fact that about one third of the cases 
were selected on the basis of their known positivity. 
A general matter of concern regarding the SISH technology could be that in 
contrast to FISH results, which were often analyzed by one or a small group 
of people in an institution, SISH signals would theoretically be readable by 
any surgical pathologist during routine work. This restriction implied in the 
FISH analysis, which is also recommended by national and international 
breast cancer working groups, is advantageous in terms of inter-observer 
consistency. Therefore, although the consistency in our study was high, 
specialization and division of work, as it is common practice in most breast 
centers, should also be applied for SISH analyses. 
 
In contrast to previous studies, our study assessed the usability of SISH in 
cytologic specimens. The use of hormone receptor analyses as well as other 
immunohistochemical stains on cytologic specimen has already been 
demonstrated long ago (13). Recently, Nassar et al. evaluated new 
monoclonal antibodies against hormone receptors and Her-2 on cell blocks 
(14). Our results demonstrate for the first time that Her-2/neu amplification 
status assessments with SISH can be performed with high reliability on 
cytologic specimens. The rare discrepancies were mostly due to the 
intratumoral hererogeneity among the cells, an inherent tumor characteristic. 
 
Many specimens in most modern cytologic laboratories are nowadays 
preferentially prepared and evaluated simultaneously on both direct smears 
and cell blocks, allowing for the analysis of different aspects of the examined 
tissue. However, the examiner interpreting study results must not forget the 
inherent important biological differences between three dimensional direct 
smears of intact cells and two dimensional cuts of the tissue. During cutting of 
the specimen for histological processing, substantial parts of cells are 
discarded and will not be appreciated upon later microscopic analysis. This 
truncation effect must be taken into account in the quantitative studies 
pertaining to the content of the nucleus, such as counting signals of an in situ 
hybridization reaction. The consideration of the cell geometry plays an 
important role in evaluating chromosome polysomy, as shown by Bubendorf 
for EGFR FISH, where the cut off values established for histology specimen 
must not be applied when interpreting signals on cytology specimens from 
non small cell lung cancer (20). The effect of the sample type (smear vs. 
paraffin cut) on evaluating gene amplification is less pronounced and could 
not be observed in our study group. 
An important biological point to be addressed is the inability to distinguish 
invasive carcinoma cells from in situ carcinoma when interpreting signals on 
cytology specimens from primary tumors. Therefore careful selection of the 
samples which are suitable for submission to SISH is crucial to the 
optimization of results. No such problem exists for metastastic lesions, as 
pleural effusions or lymph node metastases.  
The major practical limitation of SISH technique on cytological specimen was 
the presence of too few tumor cells on some scarcely cellular samples .and 
the fact that some cells on the smear might also get lost during processing. 
Another difficulty faced in this study was reliable distinction of cancer cells 
from non-malignant epithelial cells and lymphocytes in faintly counterstained 
SISH specimens. The comparison with the hematoxylin/eosin or 
Papanicolaou stain was very helpful in these cases. Air drying and other 
artifacts (which are more common in cytologic than histologic samples) can 
also hinder correct SISH evaluation. It was also notable that the cases with 
discrepantly non-amplified SISH results were at least one year old or older 
and consisted of direct smears and not cell block specimens. This fact 
suggests a diminished sensitivity of the SISH after longer storage times of 
direct smears and confirms the value of preserving parts of cytologic samples 
in the form of cell blocks for later ancillary studies. However, our review of 
these cases concludes that heterogeneity of the tumor in terms of Her-2/neu 
gene amplification is the main factor leading to discrepancies, especially when 
analyzing small amounts of cancer cells.. 
 
We conclude that the determination of the Her-2/neu gene amplification status 
in cytologic breast cancer specimens using automated silver enhanced in situ 
hybridization (SISH) is a reliable and consistent technique, well suited for 
routine application in surgical pathology, if the evaluation of Her-2 status is 
indicated. 
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Figure legend 
Figure 1 SISH signals in cytologic breast cancer specimens. Cell block (A/B) 
and cytologic smear specimens (C/D) without (A/C) and with (B/D) 
amplification of the Her-2/neu gene status. The red chromosome 17 signals 
appear larger than the black Her-2 signals as best seen in the non-amplified 
probes. In the amplified samples the Her-2 signals dominate the picture with 
multiple accumulated intranuclear black signals (Original magnification 650x). 
Insets show the corresponding FISH.  
A – Cell block of a pleural effusion in a patient (80 year old) with a history of 
breast cancer. Both SISH and FISH were performed on the same specimens. 
B – SISH on the cell block of the fine needle biopsy of the breast tumor in a 
67 year old patient. FISH was performed on the tumor which was resected 
one week later. 
C and D – In both cases SISH on the direct smear of the FNA of the lymph 
node metastasis. FISH was in both cases performed on the core biopsy of the 
breast tumor taken at the same time. C: 45 year old patient and D: 69 year old 
patient 
 
 

